Glenmark Pharmaceuticals Ltd NSE  /  BSE

Pharmaceuticals, Mid Cap

11 Aug 2020 | 03:59 PM

476.95
5.80 (1.23%)

Independent Research

theScreeners

We bring you Independent research views from famous names like Reuters and theScreeners to help improve your investing results and create wealth

Star Rating

Initiated on 01-01-70

Target Price

Performance parameters

  • Earnings Revision Trend

    Analysts negative since 07-Apr-2020

    Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 07-Apr-2020 at a price of 227.95.

  • Valuation Rating

    Moderately undervalued

    Based on its growth potential and our own criteria, at its current price the stock is moderately undervalued.

  • MT Tech Trend

    Trend positive since 14-Apr-2020

    The forty day Medium Term Technical Trend is positive since 14-Apr-2020. The confirmed Technical Reverse point (Tech Reverse - 1.75%) is 277.905.

  • 4W REL Performance

    vs. SENSEX30

    The four week relative overperformance versus SENSEX30 is 46.050.

Risk parameters

  • Risk Zone

    Moderate

    The stock has been on the moderate-sensitivity level since 17-Mar-2020.

  • Bear Market

    Average sensitivity to market corrections

    On average, the stock is likely to decline with the index.

  • Bad News

    Fair market sanction in case of specific pressure

    When the stock's pressure is specific, the market sanction on average is 444%.

  • Beta

    56 Low sensitivity to SENSEX30

    For 1% of index variation, the stock varies on average by 56%.

  • Correlation

    0.3 Weak correlation to SENSEX30

    Stock movements are strongly independent of index variations.

  • Value at Risk

    Rs.80.89 The medium term value at risk is estimated at 80.89 or 0.24000%

    The value at risk is estimated at 80.89. The risk is therefore 0.24000%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.

Other parameters

  • LT Growth

    11.44 Current year to 2022 annualized estimate

    The annualized growth estimate is for the current year to 2022.

  • P/E Ratio

    10.97 Estimated PE for 2022

    The estimated PE is for the year 2022.

  • G/PE Ratio

    1.1 18.255% discount to expected growth

    A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 0.9 indicates that the stock's price presents a discount to growth of 18.255%.

  • Dividend Yield

    0.63% Dividend is largely covered by profits

    The twelve month estimated dividend yield represents 6.952% of earnings forecasts.

  • Global Evaluation

    Neutral

    The stock is classified in the neutral zone since 01-May-2020.